Arrivi Alessio, Pucci Giacomo, Placanica Attilio, Bier Nicola, Sordi Martina, Dominici Marcello, Carnevale Roberto, Tanzilli Gaetano, Mangieri Enrico
Unit of Interventional Cardiology, Santa Maria University Hospital, Terni, Italy -
Unit of Internal Medicine, Santa Maria University Hospital, Terni, Italy.
Minerva Cardiol Angiol. 2023 Apr;71(2):147-152. doi: 10.23736/S2724-5683.22.06134-8. Epub 2022 Sep 9.
Developing strategies aimed to shorten the length of stay (LOS) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) is a healthcare goal to be pursued. We carried out a subanalysis of the GSH 2014 Trial to assess the potentiality of glutathione sodium salt infusion to impact on LOS.
100 consecutive patients with STEMI, aged more than 18 years and referred to the three enrolling centers for primary angioplasty (p-PCI), were asked to participate to the GSH 2014 Trial. Fifty patients were randomized to treatment group and fifty to placebo; treatment consisted into an intravenous infusion of glutathione sodium salt over 10 minutes before p-PCI; after interventions, glutathione was infused at the same doses at 24, 48 and 72 h elapsing time. A stepwise linear multivariate model was built in order to assess independent predictors of LOS.
Subjects receiving infusion of glutathione sodium salt had a significantly lower LOS than subjects receiving placebo (8.6±3 vs. 10.8±4 days, P=0.006). At multivariate analysis, the randomization to GSH group was negatively associated with length of stay (β±SEβ -1.64±0.74, cumulative R2 0.43, P=0.03) independently from age, sex, cardiovascular risk factors, number of treated vessels, infarct-related coronary artery (left anterior descending artery as reference) and enrolment hospital.
Results from this subanalysis support the hypothesis that an early and prolonged glutathione sodium salt administration, as antioxidant therapy to patients with STEMI, may favorably impact on LOS. Further studies with larger sample size are necessary to confirm these data.
制定旨在缩短接受直接经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者住院时间(LOS)的策略是一个有待追求的医疗目标。我们对GSH 2014试验进行了亚组分析,以评估输注谷胱甘肽钠盐对住院时间的影响潜力。
连续纳入100例年龄超过18岁、因直接血管成形术(p-PCI)转诊至三个入组中心的STEMI患者,邀请他们参与GSH 2014试验。50例患者随机分为治疗组,50例为安慰剂组;治疗方法为在p-PCI前10分钟静脉输注谷胱甘肽钠盐;干预后,在24、48和72小时时间点以相同剂量输注谷胱甘肽。建立逐步线性多变量模型以评估住院时间的独立预测因素。
接受谷胱甘肽钠盐输注的受试者住院时间显著低于接受安慰剂的受试者(8.6±3天对10.8±4天,P = 0.006)。在多变量分析中,随机分配至GSH组与住院时间呈负相关(β±SEβ -1.64±0.74,累积R2 0.43,P = 0.03),独立于年龄、性别、心血管危险因素、治疗血管数量、梗死相关冠状动脉(以左前降支为参照)和入组医院。
该亚组分析结果支持以下假设,即对STEMI患者早期和长期给予谷胱甘肽钠盐作为抗氧化治疗可能对住院时间产生有利影响。需要进行更大样本量的进一步研究以证实这些数据。